Literature DB >> 9619873

Expression of connexin32 and connexin43 gap junction proteins and E-cadherin in human lung cancer.

Y Jinn1, M Ichioka, F Marumo.   

Abstract

We used immunohistochemical staining to examine the expression of the gap junction proteins connexin32 and connexin43 and of the intercellular adhesion molecule, E-cadherin, that is thought to be a prerequisite for gap junctional intercellular communication (GJIC), in 24 specimens of human lung cancer. Connexin32 was not found in cancer tissue and there were significantly fewer spots of connexin43 in the poorly differentiated versus the well differentiated (P = 0.0005) and moderately differentiated (P = 0.0002) adenocarcinomas and in the poorly differentiated versus the well differentiated (P = 0.0182) and moderately differentiated (P = 0.004) squamous cell carcinomas of the lung. E-Cadherin was expressed in all but three cases of poorly differentiated non-small cell lung cancer that showed a heterogeneously decreased expression of E-cadherin. These findings suggest that GJIC is decreased in poorly differentiated non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619873     DOI: 10.1016/s0304-3835(98)00032-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  Altered expression and localization of connexin32 in human and murine gastric carcinogenesis.

Authors:  Hyang Jee; Ki Taek Nam; Hyo-Jung Kwon; Sang-Uk Han; Dae-Yong Kim
Journal:  Dig Dis Sci       Date:  2010-11-17       Impact factor: 3.199

Review 2.  The role of altered cell-cell communication in melanoma progression.

Authors:  Nikolas K Haass; Keiran S M Smalley; Meenhard Herlyn
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

3.  A predictive role for noncancerous prostate cells: low connexin-26 expression in radical prostatectomy tissues predicts metastasis.

Authors:  I V Bijnsdorp; L Rozendaal; R J A van Moorselaar; A A Geldof
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

4.  Clinical significance of the expression of connexin26 in colorectal cancer.

Authors:  Shinya Nomura; Kiyoshi Maeda; Eiji Noda; Toru Inoue; Shinya Fukunaga; Hisashi Nagahara; Kosei Hirakawa
Journal:  J Exp Clin Cancer Res       Date:  2010-06-21

5.  Cx31.1 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis.

Authors:  Deqiang Zhang; Chengwen Chen; Yuan Li; Xuping Fu; Yi Xie; Yao Li; Yan Huang
Journal:  J Cell Mol Med       Date:  2012-05       Impact factor: 5.310

6.  Dominant negative connexin26 mutation R75W causing severe hearing loss influences normal programmed cell death in postnatal organ of Corti.

Authors:  Ayako Inoshita; Keiko Karasawa; Megumi Funakubo; Asuka Miwa; Katsuhisa Ikeda; Kazusaku Kamiya
Journal:  BMC Genet       Date:  2014-01-03       Impact factor: 2.797

7.  Connexin43 Suppresses Lung Cancer Stem Cells.

Authors:  Randall J Ruch
Journal:  Cancers (Basel)       Date:  2019-02-02       Impact factor: 6.639

8.  Higher incidence of lung adenocarcinomas induced by DMBA in connexin 43 heterozygous knockout mice.

Authors:  Krishna Duro de Oliveira; Marcello Vannucci Tedardi; Bruno Cogliati; Maria Lúcia Zaidan Dagli
Journal:  Biomed Res Int       Date:  2013-10-03       Impact factor: 3.411

9.  Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.

Authors:  Cédric Poyet; Lorenz Buser; Filip Roudnicky; Michael Detmar; Thomas Hermanns; Doris Mannhard; Andrej Höhn; Jan Rüschoff; Qing Zhong; Tullio Sulser; Holger Moch; Peter J Wild
Journal:  J Clin Pathol       Date:  2015-08-06       Impact factor: 3.411

10.  Connexin 43 Upregulation in Mouse Lungs during Ovalbumin-Induced Asthma.

Authors:  Yin Yao; Qing-Xiang Zeng; Xue-Quan Deng; Guan-Nan Tang; Jie-Bo Guo; Yue-Qi Sun; Kun Ru; Alicia N Rizzo; Jian-Bo Shi; Qing-Ling Fu
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.